Turnstone Biologics Corp. (NASDAQ: TSBX) was downgraded by analysts at Bank of America Co. from a "neutral" rating to an "underperform" rating.
Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting [Yahoo! Finance]
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Turnstone Biologics Corp. (NASDAQ: TSBX) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating.